Literature DB >> 6324821

Kinetics of inhibition of angiotensin converting enzyme by captopril and by enalapril diacid.

C H Reynolds.   

Abstract

Using a continuous spectrophotometric assay, inhibition of angiotensin converting enzyme by captopril and by the active diacid derivative of enalapril was reinvestigated. The onset of inhibition was comparatively slow, but the inhibition achieved was stronger than previous estimates: approximate Ki-values were 0.3 nM for captopril and 0.06 nM for enalapril diacid. The rate-constants for association and dissociation of these enzyme-inhibitor complexes were estimated, and half-times of approximately 12 min for the captopril complex and 60 min for the enalapril diacid complex were calculated. The rate of dissociation of the captopril-enzyme complex was measured directly by reacting the thiol group in free captopril with 5,5'-dithiobis(2-nitrobenzoic acid) and observing the reactivation of the enzyme; a half-time of approximately 30 min was obtained. Therefore the release of these inhibitors from the enzyme may be slow enough to affect the duration of their hypotensive action.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324821     DOI: 10.1016/0006-2952(84)90180-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 2.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

3.  BW A575C, a chemically novel agent with angiotensin converting enzyme inhibitor and beta-adrenoceptor-blocking properties.

Authors:  G Allan; D Cambridge; G W Hardy; M J Follenfant
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

4.  Exploring the Role of Residue 228 in Substrate and Inhibitor Recognition by VIM Metallo-β-lactamases.

Authors:  Maria F Mojica; S Graciela Mahler; Christopher R Bethel; Magdalena A Taracila; Magda Kosmopoulou; Krisztina M Papp-Wallace; Leticia I Llarrull; Brigid M Wilson; Steven H Marshall; Christopher J Wallace; Maria V Villegas; Michael E Harris; Alejandro J Vila; James Spencer; Robert A Bonomo
Journal:  Biochemistry       Date:  2015-05-12       Impact factor: 3.162

5.  A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system.

Authors:  Karina Claassen; Stefan Willmann; Thomas Eissing; Tobias Preusser; Michael Block
Journal:  Front Physiol       Date:  2013-02-08       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.